Related Experiment Video
Updated: Aug 31, 2026

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
Published on: June 2, 2022
Accelerated coronary artery calcification in mildly reduced renal function of high-risk hypertensives: a 3-year
Michael Bursztyn1, Michael Motro, Ehud Grossman
1Department of Medicine, Hadassah University Hospital, Mount Scopus, Jerusalem, Israel. bursz@cc.huij.ac.il
Insights
Mild renal dysfunction significantly accelerates coronary artery calcifications. This progression is two-fold greater in patients with reduced kidney function compared to those with normal function.
Area of Science:
- Cardiology
- Nephrology
- Medical Imaging
Background:
- Coronary artery calcifications (CAC) are a marker of atherosclerosis.
- Renal dysfunction is increasingly recognized as a cardiovascular risk factor.
- The impact of mild renal dysfunction on CAC progression requires further investigation.
Purpose of the Study:
- To investigate the association between mild renal dysfunction and the progression of coronary artery calcifications.
- To quantify the effect of reduced creatinine clearance on atherosclerosis burden in high-risk hypertensive patients.
Main Methods:
- Prospective study of 313 high-risk hypertensive patients over 3 years.
- Coronary artery calcifications assessed using dual-section spiral computed tomography (total coronary artery calcium score).
- Patients categorized into renal dysfunction (creatinine clearance ≤ 60 ml/min) and normal renal function groups.
Main Results:
- Coronary artery calcium score progression was two-fold higher in the renal dysfunction group compared to the normal group (P = 0.006).
- Mild renal dysfunction was an independent predictor of accelerated CAC progression (OR 2.1).
- Thiazide-based therapy was associated with faster CAC progression than nifedipine.
Conclusions:
- Mild renal dysfunction accelerates coronary artery calcifications.
- This effect is independent of traditional cardiovascular risk factors.
- Renal function status should be considered in cardiovascular risk assessment.
Objective:
To examine the effect of mild renal dysfunction on coronary artery calcifications.
Methods:
We examined the progression of coronary atherosclerosis, as measured by dual-section spiral computed tomography, using the total coronary artery calcium score as a quantitative measure of the burden of atherosclerosis. Of 547 high-risk Israeli hypertensive patients, who were participants of the prospective calcification study (a side-arm of the international INSIGHT study), 313 patients completed the 3-year follow-up. Subjects were studied upon entry (on placebo) and again after 3 years of treatment (nifedipine or thiazide). Patients were divided into two groups depending on their creatinine clearance: (i) = 60 ml/min, renal dysfunction (RD) (n = 53) and (ii) > 60 ml/min, normal renal function group (n = 263).
Results:
Blood pressure, hypercholesterolemia, and smoking did not differ between the groups. After 3 years of treatment, blood pressure control was similar, whereas the total coronary artery calcium score progression was two-fold greater in the RD than the normal group (156 +/- 32 versus 64 +/- 8, respectively) (P = 0.006). In a multiple logistic regression analysis, the odds ratio (OR) for total coronary artery calcium score progression was higher for the RD group (2.1) [95% confidence interval (CI) 1.2-3.7]. Gender, body mass index, smoking, cholesterol, family history of ischaemic heart disease and diabetes were not significant predictors. Thiazide-based antihypertensive therapy predicted a faster progression compared to nifedipine (OR 1.66, 95% CI 1.09-2.51).
Conclusions:
Mild renal dysfunction accelerates coronary artery calcifications, above and beyond conventional risk factors.
Related Concept Videos
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Coronary Artery Disease I: Introduction
Coronary Artery Disease IV: Preventive Measures
Chronic Kidney Disease III: Interprofessional Care
Atherosclerosis III: Management
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
